Feb 1, 2024
- Feb 8, 2025

Optimal Contemporary Management of Hypertrophic Cardiomyopathy: The Importance of Early Diagnosis and Targeted Therapy

EARNed Credits


AMA PRA Category 1 CreditTM



Journal Supplement to The American Journal of Cardiology

Hypertrophic cardiomyopathy (HCM) is a complex, heterogeneous disorder that affects approximately 1 in every 500 persons worldwide and about 750,000 Americans. It is characterized by left ventricular hypertrophy that is usually asymmetric, with enlarged myocytes in disarray, unexplained by loading conditions. Obstruction to left ventricular outflow occurs in approximately 60% of patients. The natural history and cardiac morphology of HCM are quite heterogeneous. Although most patients with HCM are asymptomatic or mildly symptomatic, a minority are disabled by dyspnea, angina, or syncope, develop advanced heart failure, or die suddenly.  Many patients fail supportive care and require septal reduction to relieve symptoms and ICD implantation to protect against lethal arrhythmias. A signal advance in the management of obstructive HCM was recently achieved with the approval of the first cardiac myosin inhibitor that targets HCM pathophysiology and may delay or even avert the need for septal reduction therapy.  In this special supplement to AJC our international panel of expert authors update learners on current best management of this challenging disease.

Who Should Attend

Healthcare providers across the cardiac care spectrum, including cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons, sports cardiologists and other sprots medicine specialists, as well as primary care providers and APPs who work in the cardiovascular and primary care settings.

Provided By

Course Faculty

Charles Pollack, MA, MD, FACEP, FAHA, FACC, FESC
Emergency Medicine
University of Mississippi
Jackson, Mississippi
Theodore Abraham, MD
Cardiologist Meyer Friedman Distinguished Professor of Medicine Director, UCSF Adult Cardiac Echocardiography Laboratory University of California San Francisco San Francisco, California
Eugene Braunwald, MD
Founding Chair, TIMI Study Group
Distinguished Hersey Professor of Medicine
Harvard Medical School
Boston, Massachusetts, USA
M. Roselle Abraham, MD
UCSF HCM Center of Excellence University of California San Francisco Division of Cardiology San Francisco CA
Atul D. Bali MD
Westchester Medical Center New York Medical College Valhalla, NY

Learning Objectives


An improved understanding of the prevalence, pathophysiology, unmet patient needs, and natural course of HCM


A working knowledge of imaging- and genetics-driven diagnostic and staging criteria for HCM


Improved recognition of the indications to treat, longitudinally manage, and/or refer to subspecialists, patients diagnosed with HCM


Thorough familiarity with the clinical trial data evaluating the efficacy and safety of new and emerging treatment options for HCM

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Charles V. Pollack Jr., MA, MD (Issue Editor) No conflicts of interest pertinent to the content of this activity.
M. Roselle Abraham, MD Nothing to disclose
Theodore Abraham, MD Grant/Research Support: Bristol-Myers Squibb; Cytokinetics; Echonous Ultrasound; Tenaya Therapeutics; Imbria; GE HealthCare; Philips Ultrasound
Atul D. Bali MD Nothing to disclose
Fernando Juarez Casso, MD Nothing to disclose
Aaqib Malik MD, MPH Nothing to disclose
Srihari S. Naidu MD Grant/Research Support: Bristol-Myers Squibb; Cytokinetics Consultant: Bristol Myers Squibb; CytokineticsSpeakers Bureau: Bristol Myers Squibb
Eugene V. Braunwald, MD Nothing to disclose
Carolyn Y. Ho, MD Grants/Research Support: Biomarin; Bristol Myers Squib; Pfizer; CytokineticsConsultant: Biomarin; Bristol Myers Squibb; Cytokinetics; Lexicon; Viz AI
Catherine G. Ireland, MD Stock Ownership: Amgen; Pfizer
Erika Hutt MD No conflicts of interest pertinent to the content of this activity
Milind Desai, MD, MBA Consultant: Bristol Myers Squibb; Cytokinetics; Medtronic
Barry Maron, MD Nothing to disclose
Martin Maron, MD Nothing to disclose
Ethan Rowin, MD Nothing to disclose
Lisa Salter Nothing to disclose
Hartzell Schaff, MD Nothing to disclose

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Through reciprocity with their own governing boards, learners may earn CME credits in other jurisdictions.

AcademicCME designates this enduring material for a maximum of 8.0 AMA PRA Category 1 CreditsTM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participation completion information to ACCME for the purpose of granting ABIM MOC credit.

The accreditation period for this program is February 1, 2024 through February 28, 2025.

This activity has been supported by an independent educational grant from Bristol Myers Squibb.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Review the Journal Supplement content online by advancing to the next page or at https://www.sciencedirect.com/journal/the-american-journal-of-cardiology/vol/212/suppl/S1.
  3. Complete the Post-Activity Test Questions and Evaluation.
  4. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive CME credit as indicated and MOC credit if requested.
  5. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact [email protected].

Feb 1, 2024
- Feb 8, 2025

Optimal Contemporary Management of Hypertrophic Cardiomyopathy: The Importance of Early Diagnosis and Targeted Therapy

Related Journal Supplement Courses

Hypertrophic Cardiomyopathy: New Evidence, Updated Guidelines to Support Optimal Managemen...
VTE and Anticoagulation – Guideline Updates for 2024
Shared Decision-Making and Patient Education to Promote Adherence to DOACs and Continuity ...